Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 407,928 |
|
|||||
| News | - | ||||||
| Day High | 1.88 | Low High |
|||||
| Day Low | 1.83 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cerus Corp | CERS | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.01 | -0.54% | 1.84 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.86 | 1.83 | 1.88 | 1.84 | 1.85 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,520 | 407,928 | US$ 1.86 | US$ 757,485 | - | 1.205 - 3.08 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:45:56 | 2 | US$ 1.90 | USD |
Cerus Corp Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 331.75M | 181.28M | - | 186.8M | -37.49M | -0.21 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Cerus News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CERS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.98 | 1.99 | 1.83 | 1.90 | 805,626 | -0.14 | -7.07% |
| 1 Month | 1.72 | 2.255 | 1.62 | 1.85 | 1,158,604 | 0.12 | 6.98% |
| 3 Months | 2.18 | 2.585 | 1.61 | 1.94 | 1,617,872 | -0.34 | -15.60% |
| 6 Months | 1.62 | 2.585 | 1.55 | 1.96 | 1,500,329 | 0.22 | 13.58% |
| 1 Year | 1.94 | 3.08 | 1.205 | 1.97 | 1,334,264 | -0.10 | -5.15% |
| 3 Years | 5.86 | 8.055 | 1.205 | 3.95 | 1,457,186 | -4.02 | -68.60% |
| 5 Years | 5.12 | 9.00 | 1.205 | 4.76 | 1,516,539 | -3.28 | -64.06% |
Cerus Description
| Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same. |
